CO2021014778A2 - Subunidad s1 modificada de la proteína de espícula de coronavirus - Google Patents

Subunidad s1 modificada de la proteína de espícula de coronavirus

Info

Publication number
CO2021014778A2
CO2021014778A2 CONC2021/0014778A CO2021014778A CO2021014778A2 CO 2021014778 A2 CO2021014778 A2 CO 2021014778A2 CO 2021014778 A CO2021014778 A CO 2021014778A CO 2021014778 A2 CO2021014778 A2 CO 2021014778A2
Authority
CO
Colombia
Prior art keywords
spike protein
subunit
modified
coronavirus spike
relates
Prior art date
Application number
CONC2021/0014778A
Other languages
English (en)
Inventor
Annika Kraemer-Kuehl
Hans-Christian Philipp
Thomas Min Stephan
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CO2021014778A2 publication Critical patent/CO2021014778A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere, entre otras cosas, a una proteína de espícula de coronavirus aviar recombinante o fragmento de esta que comprende una mutación en la posición de aminoácido 267 en cisteína. Además, la presente invención se refiere a una composición inmunógena que comprende un coronavirus aviar con dicha proteína de espícula
CONC2021/0014778A 2019-05-10 2021-11-02 Subunidad s1 modificada de la proteína de espícula de coronavirus CO2021014778A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19173821 2019-05-10
EP19212627 2019-11-29
PCT/EP2020/062526 WO2020229248A1 (en) 2019-05-10 2020-05-06 Modified s1 subunit of the coronavirus spike protein

Publications (1)

Publication Number Publication Date
CO2021014778A2 true CO2021014778A2 (es) 2021-11-19

Family

ID=70471064

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014778A CO2021014778A2 (es) 2019-05-10 2021-11-02 Subunidad s1 modificada de la proteína de espícula de coronavirus

Country Status (10)

Country Link
US (2) US11512115B2 (es)
EP (1) EP3965812A1 (es)
JP (2) JP2022531731A (es)
KR (1) KR20220007155A (es)
CN (1) CN114126645A (es)
BR (1) BR112021022651A2 (es)
CO (1) CO2021014778A2 (es)
IL (1) IL287763A (es)
MX (1) MX2021013743A (es)
WO (1) WO2020229248A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941091A (zh) * 2021-03-17 2021-06-11 吉林大学 一种猪血凝性脑脊髓炎dna疫苗及其制备方法
GB202107057D0 (en) 2021-05-18 2021-06-30 Univ York Glycosylation method
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN114276423B (zh) * 2021-12-21 2023-04-07 易康生物(苏州)有限公司 猪传染性胃肠炎病毒的s蛋白突变体及其应用
KR102597501B1 (ko) 2022-12-19 2023-11-03 주식회사 티지네트워크 Rf필터 검사 및 학습 시스템과 그 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0218625B1 (en) * 1985-03-29 1995-04-05 Btg International Limited Infectious bronchitis virus spike protein
WO2001009290A2 (es) 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Serotipo de virus de bronquitis infecciosa aviar
ATE463253T1 (de) 2000-02-29 2010-04-15 Wyeth Llc In ovo schutz gegen infektiöse bronchitis
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
US8679504B2 (en) 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
GB0911794D0 (en) * 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
US20140141043A1 (en) 2012-11-16 2014-05-22 Auburn University Compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
GB201308057D0 (en) * 2013-05-03 2013-06-12 Pirbright Inst The Protein
WO2015143335A1 (en) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
US9790474B2 (en) 2014-07-24 2017-10-17 University Of Georgia Research Foundation, Inc. Attenuation of infectious bronchitis virus variant GA-13
US9764025B2 (en) 2014-10-20 2017-09-19 Auburn University Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced
JP6874023B2 (ja) 2016-06-16 2021-05-19 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 伝染性気管支炎ウイルスに対するワクチン
US10329538B2 (en) 2017-01-27 2019-06-25 University Of Georgia Research Foundation, Inc. Live attenuated Arkansas serotype infectious bronchitis virus vaccine
US10772953B2 (en) * 2017-08-09 2020-09-15 Auburn University Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
US20190062373A1 (en) 2017-08-30 2019-02-28 Peption, LLC Method of generating interacting peptides
EP3873515A1 (en) 2018-10-31 2021-09-08 Boehringer Ingelheim Vetmedica GmbH H52 ibv vaccine with heterologous spike protein
EA202191145A1 (ru) 2018-10-31 2021-08-23 Бёрингер Ингельхайм Ветмедика Гмбх Вакцина виб 4/91 с гетерологичным шиповидным белком

Also Published As

Publication number Publication date
KR20220007155A (ko) 2022-01-18
CN114126645A (zh) 2022-03-01
IL287763A (en) 2022-01-01
JP2024028744A (ja) 2024-03-05
US20200354410A1 (en) 2020-11-12
JP2022531731A (ja) 2022-07-08
MX2021013743A (es) 2021-12-10
BR112021022651A2 (pt) 2021-12-28
US20230340028A1 (en) 2023-10-26
EP3965812A1 (en) 2022-03-16
US11512115B2 (en) 2022-11-29
US11999766B2 (en) 2024-06-04
WO2020229248A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
CO2021014778A2 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BRPI0606687A2 (pt) composições nutracêuticas
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CO5720212A1 (es) Composicion de anticuerpo her2
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
BR112016024494A8 (pt) análogo de peptídeo e seu uso
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
EA200802128A1 (ru) Новые нутрицевтические композиции
PE20210553A1 (es) Variantes e isoformas de anticuerpos con actividad biologica reducida
AR120891A1 (es) Proteína rsv f mutante y su uso
CO2020013552A2 (es) Formulación de anticuerpos
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
AR087094A1 (es) Formulaciones que estabilizan proteinas
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
PH12021550441A1 (en) Modified pedv spike protein
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
MX2021013702A (es) Subunidad s2 modificada de la proteina de espicula de coronavirus.